Clinical trials: aldesleukin
Leukemia
Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill acute myeloid leukemia cells. Histamine dihydrochloride may prolong remission and reduce the risk of relapse in patients with acute myeloid leukemia in…
- Trial name
- NCT00003991
- Testing
- aldesleukin, histamine dihydrochloride
- Where
- 118 sites in United States, Australia and 10 more
- Volunteers
- 360 people
- Sponsor
- Maxim Pharmaceuticals
Alopecia Areata
Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe and Resistant Alopecia Areata
Alopecia areata is an autoimmune disease associated with infiltration of cluster of differentiation 4(CD4 +) and cluster of differentiation 8 (CD8) + cells around the hair follicles.
- Trial name
- IL2 (NCT01840046)
- Testing
- Interleukin-2
- Where
- France
- Volunteers
- 4 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Ischemic Heart Disease
Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes
The mainstay for treatment for acute coronary syndrome (ACS) focusses on re-establishing and maintaining the patency of vessels following coronary plaque disruption, through the use of anti-platelets and anticoagulants.
- Trial name
- LILACS (NCT03113773)
- Testing
- Proleukin
- Where
- United Kingdom
- Volunteers
- 41 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Melanoma (Skin)
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether combining melanoma vaccine with interleukin-2 is more effective than vaccine therapy alone in treating metastatic…
- Trial name
- NCT00019669
- Testing
- aldesleukin, fowlpox virus vaccine vector, gp100 antigen
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Crohn Disease
Low Dose IL-2 for the Treatment of Crohn's Disease
The purpose of this study is to determine the safety and maximum effective dose (MED) of Interleukin-2 in subjects with moderate-to-severe crohn's disease.
- Trial name
- NCT04263831
- Testing
- Interleukin-2 (aldesleukin).
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Boston Children's Hospital
Alzheimer Dementia (AD)
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
Alzheimer's disease (AD) is the most common cause of dementia. Despite major research efforts, effective treatments that slow or stop disease progression remain limited.
- Trial name
- NCT07651319
- Testing
- IL-2 (Aldesleukin), Semaglutide Plus IL-2
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Methodist Hospital Research Institute
Autoimmune Hemolytic Anemia
Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment
The investigators have demonstrated that the mean percentage of circulating CD8+ regulatory T (CD8 Tregs) cells is significantly higher in patients with warm hemolytic anemia (wAHAI) in remission than in controls and is…
- Trial name
- ANEMIL (NCT02389231)
- Testing
- Interleukine-2
- Where
- France
- Volunteers
- 2 people
- Sponsor
- University Hospital, Bordeaux
Melanoma (Skin)
Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as interleukin-2 and interferon alfa stimulate a person's white blood cells to kill…
- Trial name
- NCT00014092
- Testing
- aldesleukin, recombinant interferon alfa, sargramostim
- Where
- 3 sites in United States
- Sponsor
- Saint Francis Hospital
Metastatic Melanoma, Skin Cancer
Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...
Background: An experimental treatment for metastatic melanoma involves cell therapy, in which researchers take white blood cells (lymphocytes) from the tumor tissue, grow them in the laboratory in large numbers, and then use the…
- Trial name
- NCT01319565
- Testing
- Aldesleukin, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor
Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors
The primary purpose of this study is to evaluate the safety of the tumor-specific TCR-T cells in the treatment of advanced Solid Tumor .
- Trial name
- NCT03891706
- Testing
- tumor-specific TCR-T cells, Interleukin-2
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangzhou FineImmune Biotechnology Co., LTD.
HIV Infections
Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3
The purpose of this study is to evaluate the safety and tolerability of giving IL-2 plus anti-HIV (antiretroviral) therapy to HIV-positive patients with CD4 cell counts (cells of the immune system that fight infection) of at…
- Trial name
- NCT00000948
- Testing
- Aldesleukin, ART
- Where
- 2 sites in Thailand
- Volunteers
- 72 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Coronary Artery Disease, Myocardial Infarction (MI)
Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T Cells
The primary goals of this study are to compare the differences in tissue-resident Treg gene signature for activation, proliferation, and suppressive function using single-cell/-nucleus RNA sequencing in patients treated with…
- Conditions
- Coronary Artery Disease, Myocardial Infarction (MI), CABG
- Trial name
- Leuk-ALIVE (NCT07610538)
- Testing
- Interleukin-2 (Aldesleukin), Standard care
- Where
- 2 sites in United Kingdom
- Volunteers
- 24 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Melanoma, Malignant Melanoma
Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
Background: Most therapeutic therapies for metastatic melanoma have focused on the ability of T-cell lymphocytes to kill cells of tumors.
- Conditions
- Melanoma, Malignant Melanoma, Melanoma, Experimental, Experimental Melanomas
- Trial name
- NCT00513604
- Testing
- aldesleukin, therapeutic autologous lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- National Cancer Institute (NCI)
Nephrotic Syndrome
IL-2 for Multi Drug Resistant Nephrotic Syndrome
The aim of the study is to design an open-label phase 1-2 trial to assess safety and clinical and immunologic effects of repeated administration of recombinant low dose IL2 (Proleukin) in 5 patients with idiopathic nephrotic…
- Trial name
- NCT02455908
- Testing
- Proleukin®
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- Istituto Giannina Gaslini
Stage IV Melanoma
Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma
RATIONALE: Aldesleukin may stimulate lymphocytes to kill melanoma cells. Treating lymphocytes with interleukin-21 in the laboratory may help the lymphocytes kill more tumor cells when they are put back in the body.
- Trial name
- NCT01106235
- Testing
- therapeutic autologous lymphocytes, aldesleukin, cyclophosphamide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Brain and Central Nervous System Tumors
Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme
RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00331526
- Testing
- aldesleukin, therapeutic autologous lymphocytes, adjuvant therapy
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Hoag Memorial Hospital Presbyterian
Metastatic Melanoma, Skin Cancer
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
Background: Tumor infiltrating lymphocytes (TIL) are white blood cells that have been taken from tumor tissue. The cells are modified to help them kill tumor cells, then given back to the person with cancer.
- Trial name
- NCT01369875
- Testing
- Cyclophosphamide, Fludarabine, Aldesleukin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to and kill tumor cells. Colony-stimulating factors such as GM-CSF may increase the number of immune cells found in the bone marrow or…
- Trial name
- NCT00003222
- Testing
- aldesleukin, gp100 antigen, incomplete Freund's adjuvant
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Virginia
Cancer
Adoptive Cell Therapy Across Cancer Diagnoses
This study will perform tumor-infiltrating lymphocyte (TIL)-based adoptive T-cell therapy in combination with checkpoint inhibition on cancer patients across all cancer diagnoses.
- Trial name
- NCT03296137
- Testing
- Autologous tumor-infiltrating lymphocytes, Ipilimumab, Nivolumab
- Where
- Denmark
- Volunteers
- 25 people
- Sponsor
- Inge Marie Svane
Kidney Cancer
Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells.
- Trial name
- NCT00003181
- Testing
- aldesleukin, sargramostim, vinblastine sulfate
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Hope Cancer Institute, Inc.